Avtor/Urednik		Grošel, Alenka
Naslov		Vpliv elektrogenske terapije s p53 v kombinaciji s cisplatinom na preživetje humanih celičnih linij raka prostate in raka debelega črevesa in vitro
Tip		monografija
Kraj izdaje		Ljubljana
Založnik		Medicinska fakulteta
Leto izdaje		2003
Obseg		str. 113
Jezik		slo
Abstrakt		Electroporation has proven to be a successful method of introducing genes in vitro and in vivo into the cells of various tissues. In gene therapy the use of electric pulses enables an easier passage of naked DNA through the pores temporarily created in the membrane. The exchange of DNA molecules between the internal and extra-cellular matrix is driven by the electrophoretic and electro-osmotic pressure created by the electric-pulse activity. The tumour-suppresor TP53 protein is a transcription factor and is found in very low numbers in normal cells. Different forms of stress can lead to post-translational modifications in TP53 and its stabilisation. The accumulation of TP53 triggers a transcription of the genes involved in cell-cycle inhibition or apoptosis. In most types of human cancer TP53 remains inactivated due to mutations in the p53 gene or links between TP53 and other proteins. Cisplatin is among the most frequently used chemotherapeutics in clinical treatment. It is used to treat testicular, ovarian, bladder and cervical cancers, cancers of the head and neck and small cell and non-small cell lung cancers. An important problem associated with cisplatin treatrnent is resistance or acquired resistance of the tumour cells to cisplatin. With the electroporation of tumour cells we could successfully increase the introduction of cisplatin into the cells and thus increase its anti-tumour effect. (Abstract truncated at 2000 characters)
Deskriptorji		TUMOR CELLS, CULTURED PROSTATIC NEOPLASMS COLONIC NEOPLASMS CISPLATIN PROTEIN P53 ELECTROPORATION DRUG DELIVERY SYSTEMS